Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 6/20 | 0.50 |
| ▸ | PPP5C | P53041 | 2/20 | 0.50 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.50 |
| ▸ | NPY4R | P50391 | 1/20 | 0.50 |
| ▸ | PPM1B | O75688 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18073233 | 0.85 | TFPI2 (0.47) | TFPI2PPP5CPPP2CANPY4RTSHR | |
| SCHEMBL17585970 | 0.85 | TFPI2 (0.56) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL16731276 | 0.85 | TFPI2 (0.56) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377846 | 0.85 | TFPI2 (0.56) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL16731299 | 0.85 | TFPI2 (0.56) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL18073232 | 0.82 | PPM1B (0.49) | PPM1BPTPN1PPP1CCTSHRALDH1A1 | |
| SCHEMBL18073230 | 0.82 | PPM1B (0.63) | TFPI2PPP5CPPM1BPTPN1PPP1CC | |
| SCHEMBL16731300 | 0.82 | TFPI2 (0.62) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377845 | 0.82 | TFPI2 (0.62) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL18073221 | 0.82 | TFPI2 (0.53) | TFPI2PPP5CPPP2CANPY4RPPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | DUSP1, PPP5C, DUSP15 | TFPI2 320/4885PPP5C 2/4885PPP2CA 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.